Androgen deprivation therapy in prostate cancer and risk of developing renal calculi: Results of a case-control study

• Published in: Medicina clinica Vol. 148; no. 11; p. 495
• Main Authors: Díaz Convalía, Enrique Javier, Cano-García, María Del Carmen, Miján-Ortiz, José Luis, Arrabal-Martín, Miguel, Arrabal-Polo, Miguel Ángel, Cózar-Olmo, José Manuel
• Format: Journal Article
• Language: English
• Published: Spain 07.06.2017
• Subjects: Aged; Aged, 80 and over; Androgen Antagonists - adverse effects; Androgen Antagonists - therapeutic use; Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - therapeutic use; Follow-Up Studies; Gonadotropin-Releasing Hormone - adverse effects; Gonadotropin-Releasing Hormone - therapeutic use; Humans; Incidence; Kidney Calculi - chemically induced; Kidney Calculi - epidemiology; Male; Middle Aged; Prostatic Neoplasms - drug therapy; Retrospective Studies; Risk Factors; Treatment Outcome; Cáncer de próstata; Renal stones; Androgen deprivation therapy; Tratamiento de privación androgénica; LHRH analogues; Litiasis renal; Análogos LHRH; Prostate cancer
• ISSN: 1578-8989
• DOI: 10.1016/j.medcli.2017.01.021

Androgenic deprivation therapy in prostate cancer is associated with the onset of different adverse effects, including osteoporosis and metabolic syndrome. Both are related to the onset of nephrolithiasis. The objective of this article is to study the incidence of renal stones in patients undergoing androgen deprivation therapy with LHRH analogue. Case-control study including a total of 85 patients divided into 2 groups: group 1, with 41 patients on androgen deprivation therapy, and group 2, with 44 patients not receiving androgen deprivation therapy. New-onset lithiasis was observed in 12 cases (29.3%) in group 1 compared to 2 cases (4.5%) in group 2 (P=.0001), 4.4 years after starting the androgen deprivation therapy. The estimated odds ratio was 8.69 (95% CI 1.81-41.76). The incidence of renal stones could be increased in patients receiving treatment with analogue LHRH. However, long-term prospective studies with a metabolic control are required to be able to establish the causes explaining the development of this phenomenon in patients undergoing treatment with androgen deprivation therapy.